Compare Inovio Pharmaceuticals Inc (INO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Royal Caribbean Cruises Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Royal Caribbean Cruises Ltd trades at $308 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 1045.8× Inovio Pharmaceuticals Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | RCL | |
|---|---|---|
Market Cap | $78.55M | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $365.84 |
52-Week Low | $0.66 | $246.71 |
Enterprise Value | $49.56M | $104.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Royal Caribbean (RCL) trades at $307.87, showing minimal daily movement (-0.04%) with a bullish technical signal. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 versus $3.98, and robust profitability metrics including 23.54% net income margin and 45.33% ROE. Recent news highlights strong demand trends and the pricing of $1.25 billion in senior notes to support growth initiatives.
RCL presents a compelling growth story with record bookings and improved financial health, though elevated valuation ratios (P/E 18.97, P/S 4.46) and geopolitical risks in Europe warrant caution. Analyst consensus remains positive with a $343.09 price target, suggesting approximately 11% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
